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Abstract
The cardiac and skeletal muscle sarcoplasmic reticulum ryanodine receptor Ca2+ release channels
contain thiols that are potential targets of endogenously produced reactive oxygen and nitrogen
intermediates. Previously, we showed that the skeletal muscle ryanodine receptor (RyR1) has O2-
sensitive thiols; only when these thiols are in the reduced state (pO2 ~ 10 mmHg) can physiological
concentrations of NO (nanomolar) activate RyR1. Here, we report that cardiac muscle ryanodine
receptor (RyR2) activity also depends on pO2, but unlike RyR1, RyR2 was not activated or S-
nitrosylated directly by NO. Rather, activation and S-nitrosylation of RyR2 required S-
nitrosoglutathione. The effects of peroxynitrite were indiscriminate on RyR1 and RyR2. Our results
indicate that both RyR1 and RyR2 are pO2-responsive yet point to different mechanisms by which
NO and S-nitrosoglutathione influence cardiac and skeletal muscle sarcoplasmic reticulum Ca2+
release.
Active muscle produces reactive nitrogen and oxygen species that modulate its contraction and
relaxation (1–3). The massive skeletal muscle (RyR1)1 and cardiac muscle (RyR2) ryanodine
receptors (4,5) are among the major targets of NO and related molecules in muscle (3,6–8).
NO and/or NO-related species also modulate RyR1 and RyR2 channel activity in vitro [as
measured by SR vesicle Ca2+ efflux, activity in lipid bilayers, and [3H]ryanodine binding to
RyRs (an indirect assay of RyR channel activity)]. NO and NO donors activate and inhibit the
RyRs depending on their concentrations and experimental conditions (9–13). Moreover, the
effect of submicromolar NO on RyR1 is dependent on oxygen tension (pO2) (14), requiring
low physiological O2 tension to activate the channel. In contrast, drugs such as N-ethyl-2-(1-
ethyl-2-hydroxy-2-nitrosohydrazino)ethamine (NOC-12), which generates NO, or 3-
morpholinosydnonimine (SIN-1) and S-nitrosoglutathione (GSNO), which generate a variety
of reactive nitrogen species, including peroxynitrite, nitrosonium cation (NO+), or NO itself,
can chemically modify and activate RyR1 at ambient pO2 (pO2 ~ 150 mmHg) (15–17).
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We have reported previously that, in single-channel studies, GSNO and SIN-1 activated the
purified RyR2 at ambient pO2 (18), but whether NO can directly modulate RyR2 remains
unknown. Further, whether RyR2 contains pO2-sensitive thiols that might alter responsiveness
to NO or GSNO remains unknown. In the study presented here, we examine the effects of NO,
GSNO, NOC-12, and SIN-1 on RyR2 in SR vesicles at pO2 values of ~150 and ~10 mmHg.
We report that RyR2 activity, like RyR1 activity, is dependent on pO2. But in contrast to RyR1,
NO and NOC-12 neither effectively S-nitrosylated RyR2 nor activated the channel. RyR2 was
nonetheless readily activated by GSNO and SIN-1.
EXPERIMENTAL PROCEDURES
Materials
[3H]Ryanodine was from DuPont NEN (Boston, MA). GSNO, NOC-12, monobromobimane,
and myosin light chain kinase-derived CaM binding peptide were from Calbiochem (La Jolla,
CA), and SIN-1 was from Molecular Probes (Eugene, OR). NO gas (purity of >99%, National
Welders) was scrubbed to remove O2 and nitrite by passage through an argon-purged column
filled with KOH pellets and a solution of NaOH. The concentration of NO was determined by
a hemoglobin titration assay and NO electrode (WPI Instruments, Sarasota, FL) as described
previously (14). Other chemicals were analytical grade.
SR Vesicle Preparations
SR vesicles were prepared from canine heart in the presence of protease inhibitors (100 nM
aprotinin, 1 μM leupeptin, 1 μM pepstatin, 1 mM benzamidine, and 0.2 mM
phenylmethanesulfonyl fluoride) (19). Recombinant rabbit RyR2s were expressed in human
embryonic kidney 293 cells, and crude membrane fractions were prepared as described
previously (20).
Determination of Free Thiol and S-Nitrosothiol Content, and pO2 Responsiveness of RyR2
The free thiols in RyR2 gradient fractions were assessed in situ (in cardiac SR vesicles) by the
monobromobimane fluorescence method (14). Briefly, cardiac SR vesicles were exposed to 1
mM monobromobimane in the dark at 24 °C for 1 h at a pO2 of ~10 or ~150 mmHg. After
solubilization in CHAPS, samples were loaded onto the top of a 7 to 20% continuous sucrose
gradient, centrifuged overnight at 4 °C, and fractionated. RyR2 peak fractions, determined in
parallel gradients using the RyR-specific ligand [3H]ryanodine (21), were assayed for
monobromobimane fluorescence, protein content, and protein composition by SDS-PAGE.
The S-nitrosothiol (SNO) content of RyR2 peak fractions was determined by a mercury-
coupled photolysis/chemiluminescence method (14).
[3H]Ryanodine Binding
Ryanodine binds with high specificity to the RyRs and is widely used as a probe of channel
activity because of its preferential binding to the open channel states (21). Unless otherwise
indicated, [3H]ryanodine binding to SR vesicles (0.2 mg of protein/mL) or microsomal
membrane fractions containing the recombinant RyR2s (0.4 mg/mL) was assessed at a pO2 of
~10 or ~150 mmHg by incubating samples for 4–5 h at 24 °C with 5 nM [3H]ryanodine in
medium containing 0.125 M KCl, 20 mM imidazole (pH 7.0), 0.1 mM EGTA, and Ca2+
concentrations to yield ~5 μM free Ca2+, 0.3 mM Pefabloc, 30 μM leupeptin, and additions
given in the figure legends. The level of nonspecific binding was determined using a 1000-
fold excess of unlabeled ryanodine. Aliquots of the samples were diluted with 5 volumes of
ice-cold water and placed on Whatman GF/B filters soaked with 2% (w/w) polyethyleneimine.
Filters were washed with three 5 mL volumes of ice-cold 0.1 M KCl, 1 mM KPipes buffer (pH
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7.0), and the radioactivity remaining on the filters was determined by liquid scintillation
counting, yielding bound [3H]ryanodine.
Single-Channel Recordings
Single-channel measurements were performed using Mueller-Rudin type planar lipid bilayers
containing a 5:3:2 mixture of bovine brain phosphatidylethanolamine, phosphatidylserine, and
phosphatidylcholine (25 mg of total phospholipid/mL of n-decane) (22). SR vesicles were
added to the cis (SR cytosolic side) chamber of a bilayer apparatus and fused in the presence
of an osmotic gradient [250 mM cis CsCH3SO3/20 mM trans CsCH3SO3 in 10 mM CsHepes
(pH 7.0)]. After channel activity had appeared, the trans (SR lumenal) CsCH3SO3
concentration was increased to 250 mM to prevent further fusion of membranes.
Proteoliposomes containing the purified recombinant RyR2s were recorded in a symmetrical
0.25 M KCl, 20 mM KHepes solution (pH 7.0). The trans side of the bilayer was defined as
ground. The large cytosolic regulatory region of the channels faced the cis chamber in a
majority (>98%) of the recordings (22). Channel activities were recorded before the addition
and 1 min following the subsequent addition of GSNO. Electrical signals were filtered at 2
kHz, digitized at 10 kHz, and analyzed as described previously (22).
Other Biochemical Assays
Free Ca2+ concentrations were obtained by including in the solutions the appropriate amounts
of Ca2+ and EGTA using the stability constants and computer program published by
Schoenmakers et al. (23). Free Ca2+ concentrations were verified with the use of a Ca2+
selective electrode. The protein concentrations were determined using the Amido Black
method (24).
Data Analysis
Results are given as means ± the standard error (SE). Significance of differences was analyzed
with a Student’s t test. Differences were regarded to be significant at p < 0.05.
RESULTS
Oxygen Tension-Sensitive RyR2 Thiols
As we have reported previously, S-nitrosylation and activation of RyR1 by NO are linked to
the redox state of pO2-sensitive thiols within the channel (25). We asked whether RyR2 also
contains pO2-sensitive thiols and, if so, whether the redox state of these thiols is also linked to
the modulation of RyR2 channel activity by NO. We first determined the activity of RyR2 at
low (pO2 ~ 10 mmHg) and ambient (pO2 ~ 150 mmHg) oxygen tensions, using a ligand binding
assay. With or without exogenously added GSH or GSSG, [3H]ryanodine binding was
modestly (0.87 ± 0.06 and 0.96 ± 0.04 in the presence of 5 mM GSSG, 0.73 ± 0.05 and 0.84
± 0.05 in the absence of glutathione, and 0.72 ± 0.06 and 0.81 ± 0.07 in the presence of 5 mM
GSH, all in picomoles per milligram of protein) increased in the more oxidized forms of RyR2
(at pO2 ~ 150 mmHg) (Figure 1). Thus, RyR2 activity is pO2-regulated.
The number of free thiols in RyR2-enriched sucrose gradient fractions was determined using
the thiol-specific probe monobromobimane. SDS-PAGE showed that RyR2-enriched gradient
fractions contained two protein bands with an apparent molecular mass corresponding to RyR2
and a second band with an apparent molecular mass of 100 kDa (Figure 1A). Quantitative
analysis of Coomassie-stained gels indicated that RyR2 amounted to 59 ± 5% (n = 4) of the
protein content in RyR2-enriched fractions. Under ambient oxygen tension in the absence of
glutathione, RyR2 gradient fractions contained 43.1 ± 1.8 nmol free thiols/mg of protein
(Figure 1B). The number increased to 48.5 ± 1.4 nmol free thiols/mg of protein at a pO2 of
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~10 mmHg. Furthermore, RyR2-enriched gradient fractions contained pO2-sensitive thiols
even in the presence of high concentrations of reducing equivalents comparable to those found
in intact cells [5 mM glutathione (GSH)]. The number of free thiols in the presence of 5 mM
GSH was 49.6 ± 1.8 and 58.5 ± 2.9 nmol thiols/mg of protein at pO2 values of ~150 and ~10
mmHg, respectively. The effects of oxidizing conditions produced by oxidized glutathione
(GSSG) were also probed. In the presence of 5 mM GSSG, a decrease in oxygen tension from
~150 to ~10 mmHg had a modest effect, increasing the number of free thiols from 37.5 ± 1.8
to 38.5 ± 3.8 nmol thiols/mg of protein. Thus, a good correlation between RyR2 activity and
free thiol content exists in RyR2 gradient fractions; however, because RyR2 was purified only
by 60%, the exact number of pO2-sensitive thiols in native RyR2 remains to be determined.
Physiological Concentrations of NO neither Modulate nor S-Nitrosylates RyR2 at either
Physiological or Ambient O2 Tension
We treated cardiac SR vesicles with a range of NO concentrations at pO2 values of ~10 and
~150 mmHg. We determined the activity of NO-treated RyR2 using [3H]ryanodine binding,
and the extent of S-nitrosylation in RyR2-enriched gradient fractions using a photolysis/
chemiluminescence assay (14). Unlike RyR1 (14), RyR2 was not activated or S-nitrosylated
by 1 μM NO at a pO2 of ~10 mmHg (Figure 2A and Table 1). At an ambient oxygen tension
of ~150 mmHg, physiological concentrations of NO were also without effect (Figure 2B and
Table 1). Supraphysiological amounts of NO (≥100 μM) inhibited RyR2 at both high and low
O2 tensions.
Effects of NO Donors, S-Nitrosothiols, and Peroxynitrite
Compounds capable of donating NO and/or NO+ are widely used to mimic the effects of NO
synthases in cellular studies (26). We tested the effects of NOC-12 which releases NO with a
half-time of ~6 h (27) and GSNO which releases NO with a half-time of ~3 h under our
conditions (27) [but can also modulate protein function by S-transnitros(yl)ation (28,29)]. As
shown in Figure 3, at 0.1 mM NOC-12 did not affect the binding of [3H]ryanodine to cardiac
SR vesicles at a pO2 of ~10 or ~150 mmHg or S-nitrosylated RyR2 (Table 1). In contrast,
GSNO, from 50 μM to 1 mM, activated RyR2 at either O2 tension. The activating effect of
GSNO reached a near-maximal level at 0.2 mM (Figure 3). At that concentration, the S-
nitrosothiol content in RyR2-enriched gradient fractions was increased from ~0.4 to ~4 nmol/
mg of protein (Table 1). In reasonable agreement, the free thiol content per RyR2 subunit
decreased by ~3 nmol/mg of protein in the presence of GSNO.
The effects of GSNO on RyR2 were further examined in single-channel measurements. Figure
4A shows the current fluctuations of a single RyR2 ion channel. In the left trace, the channel
was partially activated by ~0.7 μM free cis (cytosolic) Ca2+. Addition of 0.2 mM GSNO
increased the single-channel open probability (Po) ~2-fold (Figure 4A, right trace). Kinetic
analysis indicated that GSNO increased Po by increasing the number of single-channel events
[270 ± 54 vs 657 ± 57 events/min (n = 4)] without significantly changing the mean open times.
Previously, we found that NO and NOC-12 activated RyR1 via S-nitrosylation of Cys3635
which is contained within the calmodulin (CaM) binding domain of RyR1 (14, 16). S-
Nitrosylation of Cys3635 reversed the inhibitory effect of CaM on RyR1. In contrast, activation
of RyR1 by GSNO was independent of Cys3635 and CaM. Likewise, we find that the
corresponding RyR2 cysteine (Cys3602) was not required for RyR2 activation by GSNO in
single-channel measurements (Figure 4B). In [3H]ryanodine binding measurements, across the
range of Ca2+ concentrations tested (from 0.1 μM to 10 mM), GSNO activated the native RyR2
as it did the native RyR1, both with exogenous CaM (1 μM CaM) added to the medium or
following removal of endogenous CaM using 0.1 μM myosin light chain kinase-derived CaM
binding peptide (30) (Figure 5).
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We also probed the effect on RyR2 of 3-morpholinosydnomine (SIN-1), which releases both
NO and superoxide (O2−) at a 1:1 ratio, thus generating peroxynitrite (ONOO−) (31). We
previously showed that SIN-1 oxidized and thereby activated the purified RyR2 at ambient
oxygen tension (18). To determine the effects of SIN-1 on native RyR2, cardiac SR vesicles
were treated with 0–1 mM SIN-1 at pO2 values of ~10 and ~150 mmHg. SIN-1 increased the
level of [3H]ryanodine binding to cardiac SR vesicles in a concentration-dependent manner at
both O2 tensions (Figure 3). At a concentration of 0.2 mM, SIN-1 activation was associated
with the loss of ~7–9 nmol of free cysteine residues/mg of protein in RyR2-enriched gradient
fractions (Table 1).
DISCUSSION
Cardiac contractility in the healthy heart is enhanced by nNOS through S-nitrosylation of RyR2
(7). By contrast, oxidation of the RyR2 by xanthine oxidase, which coprecipitates with nNOS
and RyR2, has been assigned a role in pathophysiological states such as heart failure (7,32):
cardiac contractility may thus be enhanced or impaired through nitrosative and oxidative effects
of NO and SNO or peroxynitrite on RyR2. The exact molecular mechanisms by which NO and
SNO modulate contractility in healthy versus diseased hearts are still unclear. A major goal of
this study was therefore to characterize regulation of RyR2 activity by endogenous reactive
nitrogen species (NO, GSNO, and peroxynitrite). In addition, since cardiac tissue is low in
pO2 and frequently subjected to oxidative insults, we sought to understand the influence of
pO2 on cardiac channel activity.
Our studies suggest that GSNO may serve as a major effector of NO bioactivity in the heart.
We report that RyR2 channel function is regulated by GSNO (not NO) and sensitive to both
oxygen tension and GSH:GSSG ratio, albeit to a lesser extent than RyR1. The redox
responsiveness of RyRs correlated directly with free thiol content in RyR2-enriched gradient
fractions, indicating that RyR2 thiols are modified. These data strongly suggest a cause and
effect relationship between redox-based modification of RyR2 and channel activation. We are
not, however, able to dispositively assign the modified thiols to RyR2 because of the presence
of another contaminating protein with a molecular mass of ~100 kDa. In addition, we report
that RyR2 activation by peroxynitrite correlated with oxidation of free thiols in RyR2-enriched
gradient fractions. Overall, these data support the idea that RyR activity is regulated under
(patho)physiological conditions by GSNO and oxidation.
RyR oxidation in vivo is likely to involve different effectors under physiological and
pathophysiological conditions. Peroxynitrite formation, for example, is favored when NO and
superoxide (O2−) concentrations increase, as in the postischemic heart. Peroxynitrite is an
indiscriminant oxidant, readily oxidizing thiols to higher S-oxides and thus predisposing the
heart to cellular injury (33). Oxidation of RyR2 by peroxynitrite is likely to adversely impact
contractile function.
Mammalian tissues express three nitric oxide synthase isoforms: endothelial (eNOS), neuronal
(nNOS), and inducible (iNOS) nitric oxide synthases. In normal cardiac and skeletal muscle,
the predominant constitutive isoforms eNOS and nNOS are targeted to different subcellular
compartments with nNOS colocalizing with RyR1 and RyR2 (34). In mice with a malignant
hyperthermia mutation (RyR1-Y522S), an increased RyR1 activity increased the level of
formation of reactive nitrogen species which by S-nitrosylating the mutant channels increased
the rate of temperature-sensitive SR Ca2+ release (35). Repeated exercise in mice resulted in
an increased level of RyR1 S-nitrosylation, which may have contributed to the formation of
“leaky” channels and decreased exercise capacity (36). Functional studies with nNOS−/− and
eNOS−/− mice showed that the two isoforms have divergent effects on cardiac SR Ca2+ cycling
and thus contractility (37,38). nNOS is found by immunoelectron microscopy in cardiac muscle
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SR (39), and a selective association of nNOS with RyR2 has been reported (37). Elimination
of nNOS in cardiomyocytes led to RyR2 hyponitrosylation, increased diastolic Ca2+ levels,
and a proarrhthmic phenotype (32). It has been suggested that under physiological conditions,
nNOS may primarily generate GSNO, which can either release NO or transfer NO+ to acceptor
thiols (40). The results of this study suggest that nNOS exerts its physiological effects on
cardiac SR Ca2+ release via the transnitrosylative action of GSNO.
We showed previously that a submicromolar NO level activates RyR1 at a pO2 of ~10 mmHg
but not at a pO2 of ~150 mmHg (14). In contrast, NOC-12 activated RyR1 in a manner
independent of pO2 (16), a behavior that may result from its direct interaction with the channel.
Nonetheless, modulation of RyR1 activity by both NO and NOC-12 depends on CaM and is
mediated by S-nitrosylation of Cys3635. The same conserved cysteine in RyR2 (RyR2-C3602
vs RyR1-C3635) is part of a putative hydrophobic motif for S-nitrosylation (41). However,
neither 1 μM NO nor 0.1 mM NOC-12 [which releases NO with a peak concentration of 2.6
μM under our conditions (16)] nitrosylated RyR2 or altered RyR2 activity. RyR2 activity was
not activated by NO or NOC-12 regardless of whether CaM was present.
Under physiological conditions, GSNO can modulate protein function by release of NO or by
S-transnitros(yl)ation, the direct transfer of NO+ to cysteine thiols [S-glutathiolation by GSNO,
a minor side reaction mediated by byproducts accumulated during GSNO decomposition
(42), is unlikely to be relevant]. It is difficult to rationalize the involvement of released NO, as
neither NO itself nor NOC-12, which releases NO, can activate RyR2. We also note that the
number of thiols nitrosylated by GSNO correlated well with the total number of free thiols lost.
Taken together, our data indicate that S-nitrosylation, through NO group transfer chemistry,
is the most straightforward explanation in this case.
In conclusion, we show that RyR2, like RyR1, is an oxygen-responsive ion channel suggestive
of a class effect for RyRs and, more broadly, for a subset of thiol-regulatory channels (43).
However, whereas pO2 serves to modulate the NO responsiveness of RyR1, enhancing channel
activity at physiological pO2, RyR2 does not respond to NO. Differences in pO2 regulation
thus reflect, in part, the nature of the nitrosylating species: NO in skeletal muscle and GSNO
in the heart. Our data point to GSNO serving as a major effector of NO bioactivity in the heart.
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Control of the redox state of RyR2-enriched gradient fractions and RyR2 activity by pO2
(oxygen tension) and glutathione redox potential. (A) Coomassie-stained gel of a RyR2-
enriched sucrose gradient fraction electrophoresed through a 3 to 12% SDS-polyacrylamide
gel. (B) [3H]Ryanodine binding and free thiol content determined as described in Experimental
Procedures either in the absence (○ and ●) or in the presence of 5 mM GSH (□ and ■) or 5 mM
GSSG (△ and ▲ ) at a pO2 of ~10 mmHg (empty symbols) or 150 mmHg (filled symbols).
Data are means ± SE of three or four experiments. A linear correlation coefficient of 0.88 (n
= 22) suggests a highly significant correlation between the free thiol content of RyR2-enriched
gradient fractions and RyR2 activity (---).
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Effect of gaseous NO on [3H]ryanodine binding of cardiac muscle SR at pO2 values of ~10
and ~150 mmHg. The level of specific [3H]ryanodine binding to cardiac SR vesicles was
determined by incubating samples at ~10 (A) and ~150 mmHg (B) at the indicated initial NO
concentration for 4–5 h at 24 °C as described in Experimental Procedures. Data are means ±
SE of three or four experiments. An asterisk denotes p < 0.05, compared with each control
(−NO).
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Effects of NOC-12, GSNO, and SIN-1 on [3H]ryanodine binding of cardiac muscle SR. The
level of specific [3H]ryanodine binding to cardiac SR vesicles was determined by incubating
samples at pO2 values of ~10 (A) and ~150 mmHg (B) in the presence of the indicated initial
concentrations of NOC-12 (●), GSNO (▲), or SIN-1 (■) for 4–5 h at 24 °C as described in
Experimental Procedures. Data are means ± SE of three or four experiments. An asterisk
indicates p < 0.05, compared with each control.
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Effects of GSNO on single-RyR2 channel activities. (A) Single-channel currents (downward
deflections from closed levels, c-) of native RyR2 were recorded at −35 mV as described in
Experimental Procedures in 0.25 M CsCH3SO3 buffer in the presence of ~0.7 μM free Ca2+
cis without (left trace) and 1 min after the subsequent addition of 0.2 mM GSNO (right trace)
to the cis (cytosolic) chamber of the bilayer setup. Averaged channel parameters were as
follows in the absence and presence of GSNO: Po = 0.016 ± 0.004 and 0.037 ± 0.008, 270 ±
54 and 657 ± 57 events/min, To (open mean times) = 2.12 ± 0.33 and 3.66 ± 1.47 ms, and Tc
(closed mean times) = 242 ± 41 and 109 ± 19 ms, respectively. Channel parameters were
calculated from four recordings that contained a single channel activity. The differences of
Po, the number of channel events, and Tc between control and those with GSNO are significant
(p < 0.05). (B) Single recombinant WT and C3602S mutant channels were recorded as for
panel A in 0.25 M KCl buffer without (top trace) and after the subsequent addition of 1 mM
GSNO (bottom trace) to the cis (cytosolic) chamber of the bilayer setup. Averaged channel
parameters were as follows in the absence and presence of GSNO: for wild-type RyR2, Po =
0.03 ± 0.02 and 0.10 ± 0.08 (n = 5), respectively; for RyR2-C3602S, Po = 0.04 ± 0.02 and 0.07
± 0.03 (n = 6), respectively. The normalized Po is significant compared to each control
(−GSNO) (p < 0.05).
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Effect of GSNO on the Ca2+ dependence of [3H]ryanodine binding in the presence of
calmodulin or calmodulin binding peptide. The level of specific [3H]ryanodine binding to
cardiac SR vesicles was determined by incubating samples at pO2 values of ~10 (A) and ~150
mmHg (B) in the presence of the indicated concentrations of free Ca2+, in the absence or
presence of 0.2 mM GSNO, and in the presence of either 1 μM CaM or 0.1 μM CaM binding
peptide (CaMBP). Data are means ± SE of four experiments.
Sun et al. Page 13

























Sun et al. Page 14
Table 1
Free Thiol (SH) and S-Nitrosothiol (SNO) Contents of RyR2-Enriched Gradient
Fractions and [3H]Ryanodine Binding Levels in the Absence and Presence of NO
and Related Moleculesa






pO2 ~ 10 mmHg
none 48.5 ± 1.4 0.41 ± 0.27 0.72 ± 0.02
NO (1 μM) NDb 0.39 ± 0.14 0.71 ± 0.02
NOC-12 (0.1 mM) NDb 0.13 ± 0.13 0.73 ± 0.02
GSNO (0.2 mM) 45.6 ± 1.1 3.56 ± 0.36c 1.12 ± 0.03c
SIN-1 (0.2 mM) 39.1 ± 0.7c NDb 0.95 ± 0.06c
pO2 ~ 150 mmHg
none 43.2 ± 1.8 0.45 ± 0.27 0.85 ± 0.03
NO (1 μM) NDb 0.59 ± 0.32 0.83 ± 0.04
NOC-12 (0.1 mM) NDb 0.23 ± 0.16 0.83 ± 0.02
GSNO (0.2 mM) 40.2 ± 1.8 4.80 ± 0.30c 1.29 ± 0.03c
SIN-1 (0.2 mM) 35.7 ± 0.7c NDb 0.96 ± 0.03c
a
The amount of free thiols (SH) and the amount of S-nitrosylation (SNO) of RyR2-enriched gradient fractions were determined as described in
Experimental Procedures. The [3H]ryanodine binding level was determined as described in the legend of Figure 1 with a pO2 of ~10 or ~150 mmHg in




p < 0.05 compared with control (no addition).
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